Do you want to read an article? Please log in or register.
AVB-114 Demonstrates Clinical Benefit in Persistent Crohn's Perianal Fistulas: Randomized Cohort Results from the Multicenter STOMP2 Trial
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Magnetic resonance imaging-based simplified MaRIA scores are associated with future surgery in Crohn's disease, but modest correlation with ileo-colonoscopic inflammation limits their utility in clinical trials: results from the PROFILE trial
J Crohns Colitis
Bhandari M, Sharip MT, Noor NM, Khwaja S, Paverd H, De Paepe KN, Godfrey E, Hickman K, Patel KV, Subramanian S, Raine T, Lee JC, Kennedy NA, Upponi S, Parkes M, PROFILE Study Group
doi: 10.1093/ecco-jcc/jjag056
Inflammatory Bowel Disease
Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn's disease: post hoc results from the phase 3b SEQUENCE trial
J Crohns Colitis
Raine T, Danese S, Schreiber S, Gao X, Hanauer S, Torres J, Cunneen C, Kligys K, Huang X, Garrison A, Neimark E, Anschutz T, Crowley J, Cross RK
doi: 10.1093/ecco-jcc/jjag104
RECOMMENDED
Further Publications
Ustekinumab for fistulising perianal Crohn's disease: a randomised placebo-controlled trial from the GETAID
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Gut
Wils P, Nancey S, Messmer E, Bourreille A, Buisson A, Caillo L, Vuitton L, Altwegg R, Hébuterne X, Ernst O, Meunier P, Laurent V, Paul S, Laharie D, Vicaut E, Peyrin-Biroulet L, Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID)
doi: 10.1136/gutjnl-2026-339158
Inflammatory Bowel Disease
Integrating Intestinal Ultrasound to Clinical Trials in Patients With Crohn's Disease: Opportunities and Challenges
Inflamm Bowel Dis
Jairath V, Adsul S, Allocca M, Danese S, Dubinsky MC, de Oliveira MF, Ma C, Kucharzik T, Novak KL, Panaccione R, Bautista IR, Sands BE, Taylor SA, Wilkens R, Maaser C
doi: 10.1093/ibd/izaf196
Inflammatory Bowel Disease
Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial
Inflamm Bowel Dis
Afzali A, Danese S, Panaccione R, Rubin DT, Sands BE, Reinisch W, Panés J, Van Rampelbergh R, Terry NA, Salese L, Vetter ML, Yee J, Corbett C, van Duijnhoven W, Hisamatsu T, Andrews JM, D'Haens GR, GALAXI 1 investigators
doi: 10.1093/ibd/izag055
Inflammatory Bowel Disease
Mirikizumab Long-Term Efficacy and Safety in Patients with Crohn's disease: Results from the VIVID-2 Open-Label Extension Trial
Clin Gastroenterol Hepatol
Sands BE, Barnes EL, D'Haens G, Hisamatsu T, Regueiro M, Kelly CR, Laharie D, Hozak RR, Yu G, Gandhi R A, Lopes MU, Durand F, Protic M, Moses RE, Vermeire S
doi: 10.1016/j.cgh.2026.01.049
Inflammatory Bowel Disease
Therapeutic Benefit of Upadacitinib in Severe Post-Proctectomy (Class 4) Perianal Crohn's Disease: A Three-Patient Case Series
Inflamm Bowel Dis
Hanna LN, Quraishi B, Pelly T, Lung P, Tozer P, Hart A, Wong SY, Powell N
doi: 10.1093/ibd/izaf216
Inflammatory Bowel Disease
Real-World Effectiveness of Upadacitinib for Perianal Crohn's Disease: A Multi-Center Retrospective Study
Clin Gastroenterol Hepatol
Devi J, Patel A, Quraishi B, Dev B, Tan T, Kline M, Chowla N, Ramesh PR, Ballard DH, Huang L, Jaiprada F, Samaan S, Stone M, Khan A, Seeraj AA, Alanazi S, Xu A, Maas L, Jajoo A, Parian A, Altinmakas E, Ehman EC, Davenport MS, Li S, Chithriki M, Shukla R, McCurdy J, Yarur AJ, Bishu S, Johnson AM, Benjamin M, Dulaney D, Serre-Yu W, Deepak P
doi: 10.1016/j.cgh.2026.05.003
Inflammatory Bowel Disease
Efficacy and Safety of Risankizumab in Patients with Moderately to Severely Active Crohn's Disease: Interim Results from the SEQUENCE Open-Label Extension Study
J Crohns Colitis
Peyrin-Biroulet L, Atreya R, Danese S, Lindsay JO, Chapman JC, Anschutz T, Huang X, Zambrano J, van Haaren S, Joshi N, Duan WR, Cross RK
doi: 10.1093/ecco-jcc/jjaf213